UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000356
Receipt number R000000453
Scientific Title Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia
Date of disclosure of the study information 2006/03/20
Last modified on 2012/09/12 13:05:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia

Acronym

HSCT for aplastic anemia using alemtuzumab

Scientific Title

Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia

Scientific Title:Acronym

HSCT for aplastic anemia using alemtuzumab

Region

Japan


Condition

Condition

Aplastic anemia

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine the appropriate dose of alemtuzumab for aplastic anemia in allogeneic HSCT and to investigate whether HSCT using such dose of alemtuzumab can be safely performed.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I,II


Assessment

Primary outcomes

Survival on day 60 after transplantation
Engraftment within 60 days
Incidence of grade II to IV acute GVHD within 60 days

Key secondary outcomes

• Regimen-related toxicity
• Incidence of infectious disease
• Overall survival at day 365
• Therapeutic efficacy for aplastic anemia


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Alemtuzumab is added to the fludarabine-based regimen at 0.16 – 0.25 mg/kg per day for 6 days (days -10 to -5).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Patients with transfusion-dependent moderately severe, severe or very severe acquired aplastic anemia persisting for 6 months or longer after immunosuppressant treatment with ATG alone or in combination with cyclospoline.
(2) Patients who have an HLA-matched or 1-locus-mismatched related donor or an HLA-matched unrelated donor.
(3) ECOG performance status of 0 or 1.
(4) Good major organ functions.

Key exclusion criteria

(1) Diabetes uncontrollable even with regular insulin use.
(2) Uncontrollable hypertension.
(3) Current active infection.
(4) 5% or more malignant cell involvement in bone marrow.
(5) Abnormality in chromosome 7 detected by bone marrow G-banding or FISH.
(6) Current active cancer.
(7) Pregnant or nursing women or women who may be pregnant.
(8) Uncontrollable mental illness.
(9) Hepatitis B virus antigen-positive (HBsAg or HBeAg).
(10) HIV-positive.
(11) A history of hypersensitivity to transplant conditioning agents (fludarabine phosphate, cyclophosphamide) or agents for GVHD prophylaxis (ciclosporin, methotrexate).
(12) A history of hematopoietic stem cell transplantation.

Target sample size

38


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuichi Taniguchi

Organization

Federation of National Public Service Personnel Mutual Aid Association
Toranomon Hospital

Division name

Department of Hematology

Zip code


Address

2-2-2 Toranomon, Minato-ku,

TEL

03-3588-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yoshinobu Kanda

Organization

The University of Tokyo Hospital

Division name

Department of Hematology & Oncology

Zip code


Address

7-3-1 Hongo,Bunkyo-ku, Tokyo

TEL

03-3815-5411

Homepage URL


Email

ycanda-tky@umin.ac.jp


Sponsor or person

Institute

GCP-ISS HE0403 group

Institute

Department

Personal name



Funding Source

Organization

2004 Health and Labor Sciences Research Grant (Research on Measures for Intractable Diseases) of the Ministry of Health, Labor and Welfare.

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2006 Year 03 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 10 Month 22 Day

Date of IRB


Anticipated trial start date

2004 Year 12 Month 01 Day

Last follow-up date

2009 Year 07 Month 01 Day

Date of closure to data entry

2009 Year 07 Month 01 Day

Date trial data considered complete

2009 Year 11 Month 01 Day

Date analysis concluded

2010 Year 03 Month 01 Day


Other

Other related information



Management information

Registered date

2006 Year 03 Month 13 Day

Last modified on

2012 Year 09 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000453


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name